Lecanemab for early onset inherited Alzheimer's
Part of Brain & nervous system, Mental health clinical trials.
This trial tests a medication called lecanemab for people with early onset familial Alzheimer's disease. It aims to see if the drug can help slow cognitive decline in those with confirmed signs of Alzheimer's in their brain.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old and your symptoms started at or before age 65.
- You have been diagnosed with mild cognitive impairment or mild Alzheimer's disease, and a brain scan or spinal fluid test shows amyloid buildup.
- Your memory and thinking are still relatively good (for example, a score of 21 or higher on the MMSE test).
- You do not have other causes for cognitive decline, such as stroke, Parkinson's, or severe depression.
- You are not taking blood thinners like warfarin or direct oral anticoagulants, and you have no history of recent stroke or bleeding in the brain.
- You are able to have an MRI scan (no pacemaker, defibrillator, or severe claustrophobia).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a special near-infrared light device, combined with the medication lecanemab, can help people with mild Alzheimer's disease. It aims to see if the light therapy can slow down memory loss and improve daily function.
This trial tests a drug called donanemab in people who have early signs of Alzheimer's disease (amyloid buildup in the brain) but are still thinking clearly. The goal is to see if the drug can slow or prevent cognitive decline before memory problems start.
This study tests how lecanemab works in people with early Alzheimer’s, including those with mild dementia or mild memory problems. It aims to see if the drug can help clear brain plaques and slow down symptoms.
This study looks at how well lecanemab works for people with early Alzheimer's disease. It aims to see if the drug can help slow down memory and thinking problems.
This study tests a drug called Lecanemab in people with early Alzheimer's. It uses a blood test to see how well the drug works. You may qualify if you have mild Alzheimer's or mild cognitive impairment due to Alzheimer's and have a positive amyloid test.
This study registry collects health and brain-testing information for people with mild cognitive impairment or early Alzheimer’s dementia. It may help researchers better understand early Alzheimer disease and plan future treatments.
Hear when a new Alzheimer Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.